ANDA 205870, held by Sagent Pharms Inc. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 205870 (Palonosetron Hydrochloride), held by Sagent Pharms Inc, was first approved by FDA on Sep 19, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Rx |
| May 25, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters